A randomized clinical trial (RCT) of the efficacy of a mindfulness-based personalized health planning (MBPHP) in attenuating basal and stress-induced leukocyte beta2-integrin expressions in patients with prediabetes and comorbid depression: A proof of concept study

Abstract

Leukocyte activation is independently associated with increased fasting glucose, emotional stress, and depression. We conducted a RCT to examine the efficacy of a 22-week MBPHP in reducing fasting glucose and ameliorating depressive symptoms. Herewith, we report the effects of the MBPHP on basal and stress-induced beta2-integrin expressions in 66 unmedicated patients with prediabetes (hemoglobin A1c 5.7%–6.4%) and comorbid depression (Patient Health Questionnaire-9: 9–21). Subjects were randomized to either MBPHP (n = 32) or Support and Guided Education (SAGE, n = 34). Each arms consisted of weekly one-hour manualized group sessions. To assess stress-related CD11 changes, subjects participated in the Anger Recall Interview (ARI) at pre-intervention, post-intervention, and long- term follow-up (∼12 months). CD11a, CD11b, and CD11c expressions at baseline and post-ARI were measured using flow cytometry. Analysis revealed a significant Treatment (MBPHP vs SAGE) X Time (pre-, post-intervention, long-term follow-up) interaction for CD11b (F = 4.04, p